Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06388187 · ClinicalTrials.gov registry record · Phase 3

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.

Active
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT06388187 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 300 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06388187, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy medicine and which treatment participant get is decided by chance. The study will last for about 1½ years for each participant.

Conditions Studied

Obesity

Interventions

  • DRUG Placebo
  • DRUG Semaglutide
  • DRUG Cagrilintide

Study Locations (20)

Other

  • Hospices Civils de Lyon-Hopital Lyon Sud-1 - Pierre-Bénite
  • Hospices Civils de Lyon-Hopital Lyon Sud - Pierre-Bénite
  • Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec - Saint-Herblain
  • Centre Hospitalier Universitaire de Toulouse-Hopital Rangueil - Toulouse
  • InnoDiab Forschung GmbH - Essen
  • Wendisch - Dahl Hamburg - DZHW - Hamburg
  • AmBeNet GmbH - Leipzig
  • Institut für Diabetesforschung GmbH Münster - Dr. med. Rose - Münster
  • Forschungszentrum Ruhr KliFoCenter GmbH, Kahrmann - Witten
  • The Health Centre - Bradford-on-Avon

California

  • Aurora FDRC Inc. - Costa Mesa

Florida

  • Clinical Trial Res Assoc,Inc - Plantation

Indiana

  • Midwest Inst For Clin Res - Indianapolis

North Carolina

  • Accellacare - Wilmington

Texas

  • Velocity Clinical Res-Dallas - Dallas

Virginia

  • Washington Cntr Weight Mgmt - Arlington

Washington

  • Capital Clin Res Ctr,LLC - Olympia

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2024-06-24
Est. Completion 2026-04-21
Phase Phase 3

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06388187

The ClinicalTrials.gov registry entry for NCT06388187 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (63% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06388187 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06388187 about?

NCT06388187 is a clinical study titled "A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight". This study will look at how well CagriSema helps people with excess body weight lose weight. CagriSema is a new medicine developed by Novo Nordisk that combines cagrilintide and semaglutide. CagriSema cannot yet be prescribed by doctors. In the study, participant will either get CagriSema or dummy m...

What is the current status of trial NCT06388187?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2024-06-24. Estimated completion is 2026-04-21.

What conditions does trial NCT06388187 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06388187?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).

Who is sponsoring clinical trial NCT06388187?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06388187 being conducted?

This trial has 20 study locations across California, Florida, Indiana, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.